NASDAQ: NPCENeuropace Inc Stock
$14.00+0.25 (+1.82%)
Updated Apr 18, 2024
NPCE Price
$14.00
Fair Value Price
N/A
Market Cap
$396.82M
52 Week Low
$3.80
52 Week High
$18.15
P/E
-11.02x
P/B
19.21x
P/S
4.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.42M
Earnings
-$32.96M
Gross Margin
73.6%
Operating Margin
-37.36%
Profit Margin
-50.4%
Debt to Equity
4.21
Operating Cash Flow
-$20M
Beta
0.79
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NPCE Overview
NeuroPace, Inc. develops and sells a brain-responsive neuromodulation system that treats epilepsy. The system records continuous brain activity data, enabling clinicians to monitor patients in person and remotely. NeuroPace was incorporated in 1997 and is headquartered in Mountain View, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NPCE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NPCE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NPCE is poor value based on its book value relative to its share price (19.21x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
NPCE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NPCE due diligence checks available for Premium users.
Be the first to know about important NPCE news, forecast changes, insider trades & much more!
NPCE News
Valuation
NPCE fair value
Fair Value of NPCE stock based on Discounted Cash Flow (DCF)
Price
$14.00
Fair Value
-$0.02
Undervalued by
60,513.33%
NPCE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NPCE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.02x
Industry
28.61x
Market
41.33x
NPCE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
19.21x
Industry
3.63x
NPCE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NPCE's financial health
Profit margin
Revenue
$18.0M
Net Income
-$6.2M
Profit Margin
-34.4%
NPCE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NPCE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$107.7M
Liabilities
$87.0M
Debt to equity
4.21
NPCE's short-term assets ($92.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NPCE's short-term assets ($92.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NPCE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$3.5M
Financing
$8.2M
NPCE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NPCE vs Medical Device Stocks
Neuropace Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.